Chantix Wins the Award for the Best New Small-Molecule Drug
November 16, 2006
Pfizer's smoking cessation product Chantix wins the Scrip Award for the Best New Small-Molecule Drug.
The second Scrip Awards ceremony was held at the Grosvenor House Hotel in London on November 16, 2006 which was hosted by Gyles Brandreth, the celebrity, author and politician. The Scrip Award is a way to acknowledge the exceptionally significant chore of the pharmaceutical industry to the human civilization.
More than 600 international guests were present at the eve of the second Scrip Award Ceremony including the representatives and scientists from all pharmaceutical giants.
The judges at Scrip awards were impressed by Chantix's new approach towards the treatment of smoking, which is altogether different from other quitting medicines. The judges also liked its therapeutic benefits over other smoking cessation therapies. All these points accumulated and went in favor of Pfizer's smoking cessation product Chantix.
Other awards like BGT Lifetime Achievement award went to Prof Rolf Krebs, the Best New Biological Drug award, was won by Sanofi Pasteur MSD's human papillomavirus vaccine Gardasil, the Best Drug Delivery Advance was won by xubera (Pfizer), Pharma Company of the Year – was won by Roche.
Scrip World Pharmaceutical News is well-known as the foremost contributor of news and analysis for the global pharmaceutical and biotechnology industries. All the pharmaceutical companies around the world depend on Scrip news and information for taking major decisions which affect their business.
The potential of Chantix has been recognized by the Scrip, which means that Chantix has been proved as a very effective treatment for tobacco smoking.
Complete details of the event along with photographs and winners responses will be published in a special supplement "The Scrip Awards 2006".
Source: PRNewswire |
